Savant Capital LLC Acquires 1,702 Shares of United Therapeutics Corporation $UTHR

Savant Capital LLC lifted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 16.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,744 shares of the biotechnology company’s stock after purchasing an additional 1,702 shares during the period. Savant Capital LLC’s holdings in United Therapeutics were worth $4,923,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Machina Capital S.A.S. bought a new position in United Therapeutics during the third quarter worth about $282,000. Hantz Financial Services Inc. raised its position in shares of United Therapeutics by 282.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 941 shares of the biotechnology company’s stock valued at $394,000 after acquiring an additional 695 shares during the period. Jones Financial Companies Lllp boosted its stake in United Therapeutics by 15.5% during the 3rd quarter. Jones Financial Companies Lllp now owns 611 shares of the biotechnology company’s stock worth $264,000 after acquiring an additional 82 shares during the last quarter. Access Investment Management LLC grew its holdings in United Therapeutics by 0.9% during the third quarter. Access Investment Management LLC now owns 7,520 shares of the biotechnology company’s stock valued at $3,152,000 after purchasing an additional 65 shares during the period. Finally, UMB Bank n.a. increased its stake in United Therapeutics by 8.1% in the third quarter. UMB Bank n.a. now owns 1,414 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 106 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.8%

United Therapeutics stock opened at $478.93 on Friday. The company’s 50-day moving average price is $486.76 and its two-hundred day moving average price is $425.24. The stock has a market cap of $20.62 billion, a P/E ratio of 18.15, a P/E/G ratio of 2.57 and a beta of 0.85. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. HC Wainwright boosted their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Finally, UBS Group boosted their price objective on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 1,000 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total transaction of $510,000.00. Following the transaction, the director owned 4,190 shares in the company, valued at $2,136,900. This trade represents a 19.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $483.25, for a total value of $4,010,975.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $17,774,418.25. This represents a 18.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 542,214 shares of company stock worth $260,031,533 in the last ninety days. 10.30% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.